CliffBio
small molecule

BINOSTO

ALENDRONATE SODIUM

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyRadius Health →View the full company profile on CliffBio

Drug detail

Brand nameBINOSTO
Active ingredientALENDRONATE SODIUM
StrengthEQ 70MG BASE
Dosage formTABLET, EFFERVESCENT
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2012
Marketing statusRX

Listed patents

PatentExpiresType
9592195December 2031product

More from Radius Health

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BINOSTO patent cliff — loss of exclusivity December 2031 | CliffBio